at 8 d of age or older. Percentage of triglycerides in the total lipids of the liver and plasma increased progressively in the hypoxic newborn rats (Table 1) but beta-hydroxybutyrate and acetoacetate blood levels were normal for the age. Liver glycogen stores were depleted in the hypoxic suckling rats with fatty liver. When hypoxic rats were returned to sea level pressure for 8, 24, and 48 h before sacrifice, the level of total lipids in plasma and liver decreased, and the beta-hydroxybutyrate blood level increased significantly. Total liver lipids fell to normal values in the litter kept at sea level pressure for 24 h. Carbon monoxide produced similar results.

The fact that the rat is the only known species to show hypoxic impairment of the lipid metabolism with severe fatty liver degeneration in the perinatal period supports the existence of an unique type of lipid metabolism. Hypoxia could serve as a tool to unravel the characteristics of this apparently unique type of lipid metabolism.

REFERENCES AND NOTES

1. Stanley, C. A., Gonzales, E., and Baker, L.: Development of hepatic fatty acid oxidation and ketogenesis in the newborn guinea pig. *Pediatr. Res.*, 17: 224 (1983).
2. Chiodi, H. and Sammartino, R.: Fatty degeneration of the liver caused by high altitude hypoxia in young albino rats. *Acta Physiol. Latinoamer.*, 2: 228 (1952).
3. Chiodi, H. and Bass, R.: Hypoxic fatty liver degeneration in suckling rats. *Fed. Proc.*, 28: 1080 (1969).
4. Chiodi, H.: Study of possible causal mechanism of fatty liver of chronic hypoxic suckling rats. *Am. J. Physiol.*, 218: 92 (1970).
5. Chiodi, H. and Whitmore, S.: Lipid metabolism in suckling rats with fatty liver induced by hypoxia. *Experientia*, 30: 463 (1974).
6. Burgos, M. D., Zangheri, E. O., and Parisi, I. M.: The rat hepatocyte after exposure to high altitude: structural and chemical changes. *Q. J. Exp. Physiol.*, 55: 54 (1970).

Letter to the Editor

H. M. ROBINSON

Tropical Metabolism Research Unit, University of the West Indies, Kingston, Jamaica

The excellent review by Brasel (1), "Endocrine Adaptation to Malnutrition" is a thorough attempt to look for generalities in a confusing field. It is possible that one of the points of confusion Brasel leaves unresolved contains within it information that may help to reduce the confusion, and suggests a need for greater liaison between investigators.

Brasel points out that studies on growth hormone in malnutrition generally report high levels of this hormone, with exceptions, in cases where growth hormone levels were originally normal or diminished. The studies of Monckeberg *et al.* (2) and Robinson *et al.* (3) were cited. Both of these studies do more than this. Robinson *et al.* finds abnormally high growth hormone levels in malnourished children showing zero or negative weight gain. These levels are 2-5 times higher than during dietary treatment. Dietary treatment initiates the recovery or catch-up growth phase. Both Monckeberg *et al.* and Robinson *et al.* also report on growth hormone levels in children being treated for existing malnutrition.

Similar reports have been given by Beas *et al.* (4) and Godard (5). They point out that during treatment and/or recovery from protein-energy malnutrition, lower growth hormone values were found in children in whom growth rate was very slow [Robinson *et al.* (3) and Godard (5)] or in those in whom recovery was not yet initiated [Monckeberg *et al.* (2) Beas *et al.* (4)] and higher growth hormone levels were found in those showing satisfactory growth rates [Robinson *et al.* (3) and Godard (5)]. The administration of growth hormone to the children who were not growing significantly increased growth rates [Monckeberg *et al.* (2)]. At no time during the catch-up growth phase [Robinson *et al.* (3)] did the growth hormone levels approach the abnormally high values shown in the malnourished group.

Malnutrition is a state defined anthropometrically. As such it

is a measure of an anthropometric state achieved and not the rate of change of nutritional status or growth. The results of Monckeberg *et al.* (2), Robinson *et al.* (3), Beas *et al.* (4) and Godard (5) indicate that this rate of change, shown during recovery, is significantly related to growth hormone levels.

It would help in the interpretation of all results on malnourished children if clinical status could be specified more precisely than is possible by currently accepted anthropometric classification schemes, or by traditional clinical divisions into named disease states. It would be illogical to ask that only growth rates should be given, although they are clearly important. It is also reasonable to assume that food intakes would be important determinants of hormonal profile, and also that patients can be not only recovering, but if studied early enough after the initiation of malnutrition, their hormonal profile may also reflect their rate of deterioration.

It is difficult to see how coherence can be obtained. Is it unreasonable to suggest a discussion among principal investigators is needed to agree on an ideal list of clinical data for any malnourished child studied, and to propose the requirement for a single archive where copies of such new data could be lodged by all investigators, and made accessible to all workers in the field, permitting more easily the detection of trends of the type reported by Monckeberg *et al.* (2), Beas *et al.* (4), Godard (5), and Robinson *et al.* (3)?

REFERENCES AND NOTES

1. Brasel, J.: *Pediatr. Res.*, 14: 1299 (1980).
2. Monckeberg, F., Donoso, G., Oxman, S., Pak, N., and Meneghello, J.: *Pediatrics*, 31: 58 (1963).
3. Robinson, H., Cocks, T., Kerr, D., and Picou, D. In: 'Endocrine Aspects of Malnutrition'. Ed. L. I. Gardner and P. Amacher, 1973, 45-72.
4. Beas, F., Contreras, I., Maccioni, A., and Arenas, S.: *Br. J. Nutr.*, 26: 169 (1971).
5. Godard, C.: In: 'Endocrine Aspects of Malnutrition'. Ed. L. I. Gardner and P. Amacher, 1973, 19-30.

Response

JO ANNE BRASEL

Harbor-UCLA Medical Center, UCLA School of Medicine, Torrance, California

I completely agree with Dr. Robinson that much of the difficulty in evaluating the data on growth hormone levels in malnutrition is related to the fact that the subjects are often in differing states of malnutrition and/or recovery. It would have been very helpful to me in my review if the types of additional information on the patients and their condition, which is mentioned in the letter, had been available. I can only support the proposal that investigators in the field develop a format for recording such data for the use of others with great enthusiasm. Good luck!

Letter to the Editor

MAURICE COHEN

Wyeth Laboratories, Taplow, Maidenhead, Berkshire, England

I have just read the paper in your journal by Sampson *et al.* "Manganese Balance Studies in Infants after Operations on the Heart" 17: 263 (1983). There are one or two points that need correction. In Table 4 on page 264, it should be noted that both S26 and SMA are manufactured by Wyeth. The levels of manganese quoted for these two products are stated to be low, and if nmole/litre is converted to $\mu\text{g/litre}$ the values would read: S26 - 14.8 ± 7.7 and range, 5.8-63; and SMA - 11.8 ± 7.7 and range 3.8-23. In fact our present label claim is 160 μg per reconstituted litre, a level significantly greater than the Sampson analysis.

As fortification of our nutritional products with manganese was introduced in September 1977, the levels quoted in the article must be associated with unfortified products manu-

factured before that date. If the currently marketed product had been used in the balance study, then I am sure the results would have been quite different. I doubt that they would have concluded that the manganese content of the milks was low.

Response

B. SAMPSON AND G. B. BARLOW

*Department of Chemical Pathology, Charing Cross Hospital,
London, England*

*Department of Paediatric Surgery, Institute of Child Health,
London, England*

We read with interest the comments by Mr. Cohen on our paper "Manganese Balance Studies on Infants After Operations

on the Heart" and regret the confusion that led us to incorrectly ascribing the manufacture of some of the milk products used. The clinical treatments on which this study was based were commenced in 1974/5 and completed in 1978. Most of the samples analysed were stored frozen until analysed. It is thus probable that most of the patients studied will have been treated in the period before the supplemented milk products became available. It is not possible at this stage to say which patients may have received the supplemented product.

It is unlikely that a study conducted using supplemented milk would have led to markedly differing conclusions on the need for manganese supplementation in the surgical neonate. The ready availability of such a product will hopefully obviate the need for any further supplementation of such patients with manganese.